Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection.
about
Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis.Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureusIn vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.In vitro susceptibilities of four species of coagulase-negative staphylococci.Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations.Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis.Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin.Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus
P2860
Q34107094-117D44DE-3687-4D1D-B6A0-20A34D453003Q35116767-7C8F7540-A036-4A86-B146-103CE3D5523CQ35136601-F613C075-EB90-41E2-961E-44888F0B57F1Q35165783-B501E594-31AA-4C87-BC18-8654390AA438Q35284471-FC4DC0B9-74FF-4FD0-8D7E-679255E51FC3Q35542064-5A5325F5-0596-455C-9704-D2C81BFD4A83Q35575038-37BA0729-62E1-4AD4-87ED-57613E794474Q35643824-2A01878D-506A-4165-AFC0-7A7B83C59965Q36757553-FCF07362-1671-4DA4-A1F4-E95C35CFCFE1Q39651450-24DB1261-1AC0-451D-9EA0-7DA45EADC8D1Q39816110-CAEB85D8-1DCB-458B-BBE1-1C2BAF5EBAC6Q40087092-EBD6C451-F2BA-41C4-A5F9-013FCE7285DEQ40903164-DD97F041-39E0-4A06-9F9D-DBBF6929D552
P2860
Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Rifampin resistance. Developme ...... aphylococcus aureus infection.
@en
Rifampin resistance. Developme ...... aphylococcus aureus infection.
@nl
type
label
Rifampin resistance. Developme ...... aphylococcus aureus infection.
@en
Rifampin resistance. Developme ...... aphylococcus aureus infection.
@nl
prefLabel
Rifampin resistance. Developme ...... aphylococcus aureus infection.
@en
Rifampin resistance. Developme ...... aphylococcus aureus infection.
@nl
P2093
P1476
Rifampin resistance. Developme ...... aphylococcus aureus infection.
@en
P2093
P304
P356
10.1001/ARCHINTE.145.1.146
P407
P577
1985-01-01T00:00:00Z